CD4 and neoplasm: This observation also applied to CD69-expressing CD4+ lymphocytes (CD69 is a marker of lymphocyte activation) since these cells were not affected in the spleens of treatment and control mice (although there was a trend for higher CD4+ CD69+ cells in the affective treatment group with tumours smaller than 300 mg compared to mild or no-effect groups).